Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

The point is that Merck spent money developing and launching the Keytruda molecule once and, since then, has been continuously expanding the drug's addressable market with incremental spending ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Innovative drug development "the flavor of 2025" says Ali Pashazadeh, who discusses how the new administration will likely ...

Keytruda is now under threat not only from ... the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Akeso shared data from its study, which indicated that ivonescimab ...